In the nationwide expansion of the new round of centralized drug procurement, the product of the core product, "Ai Le", which was the only successful bid in 2018, was released. The product accounted for more than 95% of the total revenue from the German exhibition. The "heavy" product, which is "supporting" the performance, has been out of commission. It has begun to get involved in many fields, and has acquired 25.05% of Jincheng medicine. It joined hands with the hemp investment group to arrange the industrial hemp industry chain, and signed the investment letter of intent with the Changjiang medical science and Technology Co., Ltd., which will enter the field of disinfection technology. The layout of the exhibition of healthy and multi legged walking has a bearing on the performance and remains to be tested by the market.
Core products "out" drug collection nationwide expansion
In September 25th, a new round of 4+7 procurement was launched. The winning bid of Atorvastatin Calcium Tablets was Qilu pharmaceutical, Xingan pharmaceutical, Le Pu pharmaceutical and Germany exhibition health exit. In 2018, 4+7 has won the bid for health promotion (trade name "ah le").
Ah Lok's development in Germany is almost equal to all achievements. After the major asset reorganization in 2016, the German exhibition was put into the 100% stake in Jialin pharmaceutical industry and transformed into the pharmaceutical industry. In 1999, "alpha" was approved to be listed as one of the world's largest selling prescription drugs. According to China Pharmaceutical Association business data, "ah le" ranked third in the field of lipid-lowering drugs, ranked second in the Atorvastatin category, and ranked first in the domestic lipid-lowering drugs. "Ah le" products accounted for more than 95% of the German exhibition's healthy revenue.
In 2018, "4+7" urban volume procurement pilot negotiations, "ah le" exclusive bid, its sales also increased. In the first half of 2019, the market share of "ah le" ranked first in the field of domestic lipid-lowering drugs.
At the same time, German exhibition health revenue fell 44.50% in the first half of the year, "4+7" urban concentration with the volume of procurement, product sales unit price decline has become the main reason. The average selling price of "ah le" in the centralized procurement area is 3.4 yuan / box, while the average sales price in the non centralized procurement area is 17.38 yuan / box, and the average selling price of regional products sold in centralized purchase is 19.56% of the unexecuted regional price.
The gathering and exit will affect the health of Germany exhibition. According to the current round of collecting principles, the selected enterprises are 3 varieties, and the current round of procurement cycle is 2 years in principle. This means that the "healthy" "healthy" "Ai Le" wants to be finalists again, and has to wait for at least two years.
R & D investment level is relatively low, frequent investment acquisitions
While core products are missing some markets, Germany's healthy R & D is not "giving power". From the first half of 2016 to the first half of 2019, the R & D expenditure of Germany exhibition was 52 million yuan, 55 million yuan, 87 million yuan and 50 million yuan respectively, which accounted for only 5% of the proportion of R & D investment in the first half of 2019 and less than 3% in the rest of the year. In addition to "ah le", Germany exhibition health is not heavy at present.
German exhibition health also seems to be changing this situation. In the evening of September 25th, the German exhibition health announcement was signed with the Jinsheng Investment Center (hereinafter referred to as Kam Sheng Investment) to acquire the stake in Jincheng medicine, and the German Health Exhibition intends to buy 25.05% stake in Jincheng medicine, which is invested by Jinsheng investment. The transaction price is estimated to be between 2 billion 100 million yuan and 2 billion 600 million yuan. The German exhibition health premium for the acquisition, in the industry view, this is because Germany exhibition health "fancy" the leading position of Jincheng medicine subdivision, Jincheng medicine is the largest cephalosporin medicine intermediate production enterprise in the country.
A few years ago, in September 6th, the German exhibition company signed a cooperation agreement with Han Zhong Business Management Group Co., Ltd., hemp Investment Group Co., Ltd. and Han Yi Biotechnology Co., Ltd. In the view of German exhibition health, the cooperation agreement is conducive to the layout of the industrial hemp industry chain, and we will explore more opportunities for cooperation in industrial hemp seed cultivation, seed cultivation, processing and extraction, and terminal application.
In September 24th, the German Health Exhibition announced the signing of the letter of intent with the Dai Changjiang Mai Pharmaceutical Technology Co., Ltd. and its major shareholder, Dai Yan, and will enter the field of disinfection technology to expand its product line, without revealing the specific form and transaction amount of the cooperation. Changjiang pulse company is a pioneer enterprise in the field of modern disinfection technology in China. Its "Jian Zhi Su" disinfectant products are the leading products in the industry.